ReviewOncotarget2018

Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results.

Alberto Ocaña et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.